posted on 2005-07-14, 00:00authored byDai Lu, Zhaoxing Meng, Ganesh A. Thakur, Pusheng Fan, John Steed, Cindy L. Tartal, Dow P. Hurst, Patricia H. Reggio, Jeffrey R. Deschamps, Damon A. Parrish, Clifford George, Torbjörn U. C. Järbe, Richard J. Lamb, Alexandros Makriyannis
Structure−activity relationship studies have established that the aliphatic side chain plays a
pivotal role in determining the cannabinergic potency of tricyclic classical cannabinoids. We
have now synthesized a series of analogues in which a variety of adamantyl substituents were
introduced at the C3 position of Δ8-THC. Our lead compound, (−)-3-(1-adamantyl)-Δ8-tetrahydrocannabinol (1a, AM411), was found to have robust affinity and selectivity for the
CB1 receptor as well as high in vivo potency. The X-ray crystal structure of 1a was determined.
Exploration of the side chain conformational space using molecular modeling approaches has
allowed us to develop cannabinoid side chain pharmacophore models for the CB1 and CB2
receptors. Our results suggest that although a bulky group at the C3 position of classical
cannabinoids could be tolerated by both CB1 and CB2 binding sites, the relative orientation of
that group with respect to the tricyclic component can lead to receptor subtype selectivity.